U.S. markets open in 3 hours 42 minutes

NGM Biopharmaceuticals, Inc. (NGM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6300+0.1050 (+6.89%)
At close: 04:00PM EST
1.6300 0.00 (0.00%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.5250
Bid0.0000 x 3200
Ask0.0000 x 38500
Day's Range1.5190 - 1.6400
52 Week Range0.6000 - 4.8300
Avg. Volume1,138,285
Market Cap136.044M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-1.8300
Earnings DateFeb 28, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NGM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NGM Biopharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

    NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE)

  • BioPharma Dive

    NGM to go private through deal with investment firm

    The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.

  • GlobeNewswire

    NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available un